Schott Pharma Raises 2026 Forecast After Settling Key Customer Dispute

Schott Pharma AG & Co. KGaA (ETR:1SXP) raised its financial outlook for the 2026 fiscal year after settling a significant dispute with a major customer for its glass syringes. The German pharmaceutical packaging specialist said the resolution, combined with strong business performance, prompted the upward revision announced Wednesday.

Revised Outlook Exceeds Expectations

The company now anticipates stronger growth and profitability for the full year, with both key metrics surpassing prior guidance and current market consensus. The improved forecast is based on strong underlying business, fourth-quarter expectations, and the settlement agreement.

• Constant-Currency Revenue Growth: Lifted to a range of 5%-6%, up from a previous forecast of 2%-5%.
• EBITDA Margin: Targeted at 27%-28%, an increase from the prior guidance of approximately 27%.

According to a Vara Consensus report from July 6 cited by the company, current market expectations were for 3.2% revenue growth and a 27.2% EBITDA margin for the fiscal year.

Dispute Resolution and Q3 Performance

Ad

The upgraded guidance follows the resolution of a customer dispute that had led Schott Pharma to issue a profit warning in December 2025. The company stated the new agreement includes "both revenue-related and compensation components, which will have an impact on future periods."

Preliminary figures for the third quarter showed a constant-currency revenue increase of approximately 8%, well ahead of the 3.5% growth anticipated by the Vara Consensus. The preliminary Q3 EBITDA margin was approximately 27%, slightly below the market consensus of 27.5%.

Market Reaction

Following the announcement, analysts at RBC Capital Markets upgraded Schott Pharma's stock to “outperform” from “sector perform.” The broker also raised its price target on the shares to €21 from €18.

RBC noted it had been waiting for a resolution to the glass syringe dispute and "tangible evidence of an inflection" before becoming more positive on the stock. The firm said Wednesday’s announcement "ticks those boxes."